Navigation Links
New antibiotics could come from a DNA binding compound that kills bacteria in 2 minutes
Date:6/9/2009

A synthetic DNA binding compound has proved surprisingly effective at binding to the DNA of bacteria and killing all the bacteria it touched within two minutes. The DNA binding properties of the compound were first discovered in the Department of Chemistry at the University of Warwick by Professor Mike Hannon and Professor Alison Rodger (Professor Mike Hannon is now at the University of Birmingham). However the strength of its antibiotic powers have now made it a compound of high interest for University of Warwick researchers working on the development of novel antibiotics.

Dr Adair Richards from the University of Warwick said: "This research will assist the design of new compounds that can attack bacteria in a highly effective way which gets around the methods bacteria have developed to resist our current antibacterial drugs. As this antibiotic compound operates by targeting DNA, it should avoid all current resistance mechanisms of multi-resistant bacteria such as MRSA."

The compound [Fe2L3]4+ is an iron triple helicate with three organic strands wrapped around two iron centres to give a helix which looks cylindrical in shape and neatly fits within the major groove of a DNA helix. It is about the same size as the parts of a protein that recognise and bind with particular sequences of DNA. The high positive charge of the compound enhances its ability to bind to DNA which is negatively charged.

When the iron-helicate binds to the major groove of DNA it coils the DNA so that it is no longer available to bind to anything else and is not able to drive biological or chemical processes. Initially the researchers focused on the application of this useful property for targeting the DNA of cancer cells as it could bind to, coil up and shut down the cancer cell's DNA either killing the cell or stopping it replicate. However the team quickly realised that it might also be a very clever way of targeting drug-resistant bacteria.

New research at the University of Warwick, led by Dr Adair Richards and Dr Albert Bolhuis, has now found that the [Fe2L3]4+ does indeed have a powerful effect on bacteria. When introduced to two test bacteria Bacillus subtilis and E. coli they found that it quickly bound to the bacteria's DNA and killed virtually every cell within two minutes of being introduced - though the concentration required for this is high.

Professor Alison Rodger, Professor of Biophysical Chemistry at the University of Warwick, said: "We were surprised at how quickly this compound killed bacteria and these results make this compound a key lead compound for researchers working on the development of novel antibiotics to target drug resistant bacteria."

The researchers will next try and understand how and why the compound can cross the bacteria cell wall and membranes. They plan to test a wide range of compounds to look for relatives of the iron helicate that have the same mechanism for action in collaboration with researchers around the world.


'/>"/>

Contact: Adair Richards
adair.richards@warwick.ac.uk
44-077-799-81759
University of Warwick
Source:Eurekalert

Related medicine news :

1. New Ad Campaign Asks D.C. Commuters Whos Hogging Our Antibiotics?
2. Blood tests and better communication skills could cut over-prescribing of antibiotics
3. Rep. Slaughter Reintroduces Bill to Help Fight Antibiotic Resistance Crisis by Combating Misuse of Antibiotics in Animal Agriculture
4. Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act
5. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals: Risks of Overusing Antibiotics
6. Health experts urge supermarket pharmacies to get smart about free antibiotics
7. Could carbon dioxide replace antibiotics in surgery?
8. Free antibiotics: The wrong prescription for cold and flu season
9. E. coli persists against antibiotics through HipA-induced dormancy
10. Antibiotics as Loss Leaders?
11. Preventive Use of Antibiotics Cuts ICU Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Recognising that in ... from Leany Greeny delivers positive results in just three weeks. Setting the groundwork ... the metabolism. Fitting seamlessly into hectic work and family schedules, participants can lose ...
(Date:9/20/2017)... ... ... “Finn Mouseson”: follows the exciting story of a mouse as the need for adventure ... journey that will show that friends are to be gathered but home is always ... Melody Gersonde-Mickelson, who has earned a bachelor’s degree in Fine Arts from the University ...
(Date:9/20/2017)... ... 2017 , ... “Psalms of Humidity”: is a fascinating depiction of daily struggles ... one step closer to God. “Psalms of Humidity” is the creation of published author, ... made within his life are the very same things that have shaped him into ...
(Date:9/20/2017)... ... 20, 2017 , ... “They Sang At Her Funeral”: a tale of murder ... the skeletons in their closets. “They Sang At Her Funeral” is the creation of ... and married with five children and twelve grandchildren. Before becoming a writer, Annalise had ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were ... Brevard’s own Ross A. Clevens, MD, FACS . The founder and medical director ... and Reconstructive Surgeon who trained at Yale, Harvard and the University of Michigan. He ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)... 2017   OrthoAtlanta has been named the official ... Committee (AFHC) for the 2018 College Football Playoff (CFP) National ... Mercedes-Benz Stadium in Atlanta, Georgia . OrthoAtlanta ... In" campaign, participating in many activities leading up to, and ... ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
Breaking Medicine Technology: